Intellia Therapeutics Inc buy Wells Fargo & Company
Start price
08.08.25
/
50%
€9.49
Target price
08.08.26
-
Performance (%)
-20.19%
Price
18.12.25
€7.57
Summary
This prediction is currently active. The prediction for Intellia Therapeutics Inc disappoints with a performance of -20.19%. This prediction currently runs until 08.08.26. The prediction end date can be changed by Wells_Fargo___Compan at any time. Wells_Fargo___Compan has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Intellia Therapeutics Inc | -7.046% | -7.046% |
| iShares Core DAX® | -0.793% | 4.201% |
| iShares Nasdaq 100 | -2.376% | 0.857% |
| iShares Nikkei 225® | -2.701% | -0.147% |
| iShares S&P 500 | -1.689% | 1.244% |
Comments by Wells_Fargo___Compan for this prediction
In the thread Intellia Therapeutics Inc diskutieren
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "overweight" rating re-affirmed by analysts at Wells Fargo & Company.
Ratings data for NTLA provided by MarketBeat
Stopped prediction by Wells_Fargo___Compan for Intellia Therapeutics Inc
Intellia Therapeutics Inc
Start price
Target price
Perf. (%)
€9.50
28.02.25
28.02.25
€48.09
28.02.26
28.02.26
-20.29%
18.12.25
18.12.25
Intellia Therapeutics Inc
Start price
Target price
Perf. (%)
€10.22
10.01.25
10.01.25
€58.40
10.01.26
10.01.26
-25.91%
18.12.25
18.12.25
Intellia Therapeutics Inc
Start price
Target price
Perf. (%)
€13.35
18.11.24
18.11.24
€66.07
18.11.25
18.11.25
-46.02%
19.11.25
19.11.25